Full text is available at the source.
Microecological regulation in HCC therapy: Gut microbiome enhances ICI treatment
Gut microbiome may improve immune therapy for liver cancer
AI simplified
Abstract
The gut microbiome may significantly influence the effectiveness of immune checkpoint inhibitors in treating hepatocellular carcinoma (HCC).
- Specific anti-tumor cells can be activated and strengthened by immune checkpoint inhibitors (ICIs), leading to sustained tumor response rates in many HCC patients.
- Some patients with unresectable HCC do not experience long-term benefits from immunotherapy due to acquired resistance mechanisms.
- There is significant variability in how individuals' gut microbiomes respond to treatment with ICIs.
- Targeting specific gut microbes could enhance the effectiveness of checkpoint blockade therapies in HCC.
- Manipulating the gut microbiome presents a clinical strategy that may improve response rates to cancer ICI therapy.
AI simplified